Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05668988 · ClinicalTrials.gov registry record · Phase 3
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Dizal Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 324
- Enrollment target
- 20
- Study locations
NCT05668988 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Dizal Pharmaceuticals. The registered enrollment target is 324 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT05668988, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Dizal Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 324 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage. Primary objective of this study is to assess the efficacy of DZD9008 versus platinum-based doublet chemotherapy using by BICR-assessed PFS per RECIST 1.1 as primary endpoint. Approximately 320 participants are estimated to be randomized into the study. Participants enrolled will be randomized to DZD9008 or platinum-based doublet chemotherapy in a 1:1 manner, stratified by baseline brain metastasis (with/without).
Conditions Studied
Interventions
- DRUG sunvozertinib
- DRUG Pemetrexed+carboplatin
Study Locations (20)
Other
- Centro de Educación Médica e Investigaciones Clínicas, CEMIC - Buenos Aires
- Centro Diabaid - Buenos Aires
- Centro Medico Austral - Buenos Aires
- Consultorios Medicos Dr. Doreski - Fundacion Respirar - Buenos Aires
- Fundacion Cenit Para El Estudio De Neurociencias - Buenos Aires
Florida
- D&H Cancer Research Center LLC - Margate
- BRCR Medical Center Inc. - Plantation
- H. Lee Moffitt Cancer Center - Tampa
Texas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center - Dallas
- The University of Texas MD Anderson cancer center - Houston
- exas Oncology--McAllen - Weslaco
California
- OPN Healthcare, Inc. - Glendale
- Kaiser Permanente Medical Center - Vallejo
New York
- NYU Laura & Issac Perlmutter Cancer Center at NYU Langone Health - New York
- Columbia University Medical Center - New York
Ohio
- Gabrail Cancer Center Research - Canton
- OSU Brain & Spine Hospital - Columbus
Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion - Aurora
Oregon
- Providence Portland Institute Franz - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2022-12-13 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05668988
The ClinicalTrials.gov registry entry for NCT05668988 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 324 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (51% lower). The listed sponsor is Dizal Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which sunvozertinib is the first listed.
NCT05668988 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT05668988 about?
NCT05668988 is a clinical study titled "A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)". This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic th...
What is the current status of trial NCT05668988?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 324 participants. The study started on 2022-12-13. Estimated completion is 2027-10-31.
What conditions does trial NCT05668988 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05668988?
The interventions under investigation include: sunvozertinib (DRUG), Pemetrexed+carboplatin (DRUG).
Who is sponsoring clinical trial NCT05668988?
This trial is sponsored by Dizal Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05668988 being conducted?
This trial has 20 study locations across California, Colorado, Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.